Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
- 1 July 1999
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 138 (1) , 151-155
- https://doi.org/10.1016/s0002-8703(99)70261-9
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patientsThe American Journal of Cardiology, 1998
- Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozilJournal of Internal Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patientsThe American Journal of Cardiology, 1995
- Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damageThe American Journal of Cardiology, 1995
- Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combinationAtherosclerosis, 1995
- Safety of combined pravastatin-gemfibrozil therapyThe American Journal of Cardiology, 1994
- Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemiaThe American Journal of Cardiology, 1993
- Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.Circulation, 1992
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987